187 related articles for article (PubMed ID: 38040834)
21. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
23. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
24. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
25. Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer.
Ko KP; Zhang S; Huang Y; Kim B; Zou G; Jun S; Zhang J; Martin C; Dunbar KJ; Efe G; Rustgi AK; Zhang H; Nakagawa H; Park JI
bioRxiv; 2023 Feb; ():. PubMed ID: 36824935
[TBL] [Abstract][Full Text] [Related]
26. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Kim HJ; Cantor H; Cosmopoulos K
Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
[TBL] [Abstract][Full Text] [Related]
27. Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy.
Chen Q; Sun M; Li Y; Huang L; Zu C; Kuang X; Zhao J; Hao M; Ma T; Li C; Tu J; Sun C; Du Y
Nanomedicine; 2023 Sep; 53():102693. PubMed ID: 37343780
[TBL] [Abstract][Full Text] [Related]
28. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
30.
Sun S; Tang Q; Wang Y; Zhang L; Chen J; Xu M; Sun L; Cui L; Liang X
ACS Appl Mater Interfaces; 2022 Jun; ():. PubMed ID: 35657950
[TBL] [Abstract][Full Text] [Related]
31. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
Francis DM; Manspeaker MP; Schudel A; Sestito LF; O'Melia MJ; Kissick HT; Pollack BP; Waller EK; Thomas SN
Sci Transl Med; 2020 Sep; 12(563):. PubMed ID: 32998971
[TBL] [Abstract][Full Text] [Related]
32. Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy.
Subramanian M; Kabir AU; Barisas D; Krchma K; Choi K
Cell Rep Med; 2023 Jan; 4(1):100896. PubMed ID: 36630952
[TBL] [Abstract][Full Text] [Related]
33. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
[TBL] [Abstract][Full Text] [Related]
34. Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
Chen C; Li A; Sun P; Xu J; Du W; Zhang J; Liu Y; Zhang R; Zhang S; Yang Z; Tang C; Jiang X
J Control Release; 2020 Aug; 324():574-585. PubMed ID: 32473178
[TBL] [Abstract][Full Text] [Related]
35. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
[TBL] [Abstract][Full Text] [Related]
36. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
37. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
38. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
[TBL] [Abstract][Full Text] [Related]
39. A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy.
Sun Y; Han R; Wang J; Qin Y; Ren Z; Feng X; Liu Q; Wang X
J Control Release; 2022 Oct; 350():734-747. PubMed ID: 36063959
[TBL] [Abstract][Full Text] [Related]
40. Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment.
Zhang L; Bo R; Wu Y; Li L; Zhu Z; Ma AH; Xiao W; Huang Y; Rojalin T; Yin X; Mao C; Wang F; Wang Y; Zhang H; Low KE; Lee K; Ajena Y; Jing D; Zhang D; Baehr CM; Liu R; Wang L; Li Y; Lam KS
Nano Lett; 2022 Sep; 22(17):6866-6876. PubMed ID: 35926215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
